SCHEMBL4913013

SCHEMBL4913013

O=C(N/C=C/c1cccs1)Nc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 11/20 0.56
▸ ALDH1A1 P00352 7/20 0.56
▸ MEN1 O00255 5/20 0.56
▸ KMT2A Q03164 5/20 0.56
▸ SMN1; SMN2 Q16637 10/20 0.51
▸ NPC1 O15118 7/20 0.51
▸ MAPT P10636 5/20 0.51
▸ KDM4E B2RXH2 4/20 0.51
▸ LMNA P02545 3/20 0.51
▸ HCAR2 Q8TDS4 1/20 0.50
▸ TAAR1 Q96RJ0 1/20 0.47
▸ TP53 P04637 2/20 0.47
▸ EPHX1 P07099 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ CDK9 P50750 1/20 0.47
▸ CLK4 Q9HAZ1 1/20 0.47
▸ AURKA O14965 1/20 0.47
▸ PIM1 P11309 1/20 0.47
▸ CDK2 P24941 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4913015 1.00 RAB9A (0.56) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL12204615 0.87 MEN1 (0.62) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17664304 0.84 MAPT (0.48) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17664291 0.81 MAPT (0.62) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4921577 0.80 MEN1 (0.58) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4921584 0.80 MEN1 (0.58) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL18985299 0.78 RAB9A (0.74) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL18985301 0.78 RAB9A (0.74) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL19398197 0.77 ALDH1A1 (0.79) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17664295 0.77 NPC1 (0.60) RAB9AALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 — — US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 — — US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 — — US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 — — US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R RAB9A 3359/4885ALDH1A1 274/4885MEN1 4843/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R RAB9A 3359/4885ALDH1A1 274/4885MEN1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback